COMPASS Pathways to participate in upcoming Citi’s Biopharma Virtual Co-Panel Day and H.C. Wainwright Global Investment Conference
May 12 2022 - 8:00AM
COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company
dedicated to accelerating patient access to evidence-based
innovation in mental health, announced today that management will
participate in two upcoming events as follows:
- Citi’s Biopharma Virtual Co-Panel Day: panel “Mood
Disorders/Mental Health Panel” at 11:00 am ET on 18 May 2022
- HC Wainwright Global Investments Conference: presentation at
9:00 am ET on 24 May 2022
A live audio webcast of both events will be
available on the “Events” page of the Investors section of the
COMPASS website. A replay of the webcast will be available for 30
days following each event. For more information, please visit
ir.compasspathways.com.
About COMPASS PathwaysCOMPASS Pathways plc
(Nasdaq: CMPS) is a mental health care company dedicated to
accelerating patient access to evidence-based innovation in mental
health. Our focus is on improving the lives of those who are
suffering with mental health challenges and who are not helped by
current treatments. We are pioneering the development of a new
model of psilocybin therapy, in which our proprietary formulation
of synthetic psilocybin, COMP360, is administered in conjunction
with psychological support. COMP360 has been designated a
Breakthrough Therapy by the US Food and Drug Administration (FDA),
for treatment-resistant depression (TRD), and we have completed a
phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites
across Europe and North America. This was the largest randomised,
controlled, double-blind psilocybin therapy clinical trial ever
conducted, and our topline data showed a statistically significant
(p<0.001) and clinically relevant improvement in depressive
symptom severity after three weeks for patients who received a
single high dose of COMP360 psilocybin with psychological support.
We are also running a phase II clinical trial of COMP360 psilocybin
therapy for post-traumatic stress disorder (PTSD). COMPASS is
headquartered in London, UK, with offices in New York and San
Francisco in the US. Our vision is a world of mental
wellbeing. www.compasspathways.com
Availability of other information about COMPASS
PathwaysInvestors and others should note that we communicate with
our investors and the public using our website
(www.compasspathways.com), our investor relations website
(ir.compasspathways.com), and on social media (LinkedIn), including
but not limited to investor presentations and investor fact sheets,
US Securities and Exchange Commission filings, press releases,
public conference calls and webcasts. The information that we post
on these channels and websites could be deemed to be material
information. As a result, we encourage investors, the media, and
others interested in us to review the information that is posted on
these channels, including the investor relations website, on a
regular basis. This list of channels may be updated from time to
time on our investor relations website and may include additional
social media channels. The contents of our website or these
channels, or any other website that may be accessed from our
website or these channels, shall not be deemed incorporated by
reference in any filing under the Securities Act of 1933.
Enquiries Media: Lindsay Complin,
Lindsay.Complin@compasspathways.com, +44 7702 191328 Investors:
Stephen Schultz, stephen.schultz@compasspathways.com, +1 401 290
7324
COMPASS Pathways (NASDAQ:CMPS)
Historical Stock Chart
From Mar 2024 to Apr 2024
COMPASS Pathways (NASDAQ:CMPS)
Historical Stock Chart
From Apr 2023 to Apr 2024